详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Roles of KDM5 demethylases in therapeutic resistance of cancers

19| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Sichuan 610065 Chengdu, P. R. China [2]Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming 650032 Yunnan, P.R. China

出处：

DOI：

关键词： KDM5 demethylases Histone methylation Therapeutic resistance Immune evasion Cancer

摘要：

Epigenetic modifications, including the regulation of histone H3 lysine 4 methylation (H3K4me2/3), play critical roles in maintaining normal tissue homeostasis and influencing the progression of cancer, including growth, invasion, metastasis, and therapeutic resistance. The demethylation of H3K4me2/3 is orchestrated by the KDM5 demethylase family, comprising KDM5A, KDM5B, KDM5C, and KDM5D. Recent studies have highlighted the pivotal role of KDM5 demethylases in mediating resistance to cancer therapies, encompassing chemoresistance, radioresistance, immune evasion, and targeted therapy resistance. This review provides a comprehensive overview of the regulatory mechanisms by which KDM5 demethylases contribute to these resistance pathways, with a focus on their molecular targets and interactions within the tumor microenvironment. Furthermore, we discuss emerging therapeutic strategies aimed at overcoming treatment resistance by targeting KDM5 demethylases. These insights provide a foundation for the development of innovative therapeutic interventions to enhance the efficacy of existing cancer treatments, offering a transformative approach to improving long-term patient survival and quality of life.© 2025. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区生物学

小类 | 2 区遗传学

最新[2025]版：

大类 | 2 区生物学

小类 | 2 区遗传学

JCR分区：

出版当年[2024]版：

Q2 GENETICS & HEREDITY

最新[2024]版：

Q2 GENETICS & HEREDITY

影响因子： 3.5 最新[2024版] 4.7 最新五年平均 3.5 出版当年[2024版] 0 出版当年五年平均 3.5 出版前一年[2024版]

第一作者：

第一作者机构： [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Sichuan 610065 Chengdu, P. R. China [2]Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming 650032 Yunnan, P.R. China

共同第一作者：

通讯作者：

通讯机构： [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Sichuan 610065 Chengdu, P. R. China [2]Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming 650032 Yunnan, P.R. China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Discovery of novel indazole derivatives as type Ⅰ PRMTs inhibitors for the treatment of triple-negative breast cancer [2]CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers [3]Recent progress in immune evasion mechanisms of triple-negative breast cancer [4]CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [5]MCUB Inhibits PRKN-Dependent Mitophagic Degradation of PD-L1 to Promote Immune Evasion in Bladder Cancer [6]Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. [7]The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials [8]Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis [9]Management of triple-negative breast cancer by natural compounds through different mechanistic pathways [10]CRC-EBD: Epigenetic Biomarker Database for Colorectal Cancer